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IL = interleukin; mAb = monoclonal antibody; MCP = monocyte chemoattractant protein; RA = rheumatoid arthritis; sIL-6Rα = soluble IL-6 receptor α.
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Abstract
Interleukin (IL)-6 is produced at the site of inflammation and plays a
key role in the acute phase response as defined by a variety of
clinical and biological features such as the production of acute
phase proteins. IL-6 in combination with its soluble receptor
sIL-6Rα, dictates the transition from acute to chonic inflammation
by changing the nature of leucocyte infiltrate (from polymorpho-
nuclear neutrophils to monocyte/macrophages). In addition, IL-6
exerts stimulatory effects on T- and B-cells, thus favoring chronic
inflammatory responses. Strategies targeting IL-6 and IL-6
signaling led to effective prevention and treatment of models of
rheumatoid arthritis and other chronic inflammatory diseases.
Introduction
Inflammation is a complex defence mechanism in which leuco-
cytes migrate from the vasculature into damaged tissues to
destroy the agents that potentially can cause tissue injury.
Acute inflammation is a limited beneficial response, particularly
during infectious challenge, whereas chronic inflammation is a
persistent phenomenon that can lead to tissue damage. One
hallmark of acute inflammation is that initially the leucocyte
infiltrate is mostly neutrophilic, but after 24 to 48 hours mono-
cytic cells predominate [1-3]. In contrast, chronic inflammation
is histologically associated with the presence of mononuclear
cells, such as macrophages and lymphocytes [1,2].
Although several explanations have been suggested, the
mechanisms that control the transition from neutrophil to
monocyte recruitment during the transformation from acute to
chronic inflammation are poorly understood. It is possible that
the IL-6/soluble IL-6 receptor α (sIL-6Rα) complex plays an
important role in this transition.
IL-6 has a dual effect; at some levels it acts as a defence
mechanism but in chronic inflammation it is rather
proinflammatory.
Interleukin-6 in acute inflammation
The acute phase response includes changes in the concen-
trations of many plasma proteins, which are known as the
acute phase proteins (Figure 1), as well as numerous
behavioural, physiological, biochemical and nutritional
changes [4]. The acute phase proteins have been defined as
a set of plasma proteins with concentrations that increase
(positive acute phase proteins) or decrease (negative acute
phase proteins) by at least 25% in inflammatory disorders
[4,5] (Figure 1). The changes in concentrations of acute
phase proteins are largely due to changes in their production
by hepatocytes.
The cytokines that are produced during inflammatory
processes, and that participate in them, are stimulators of the
production of acute phase proteins. These inflammation
associated cytokines include IL-6, IL-1β, tumour necrosis
factor-α, interferon-γ, transforming growth factor-β [6] and,
possibly, IL-8 [7]. They are produced by a variety of cell
types, but the most important sources are macrophages and
monocytes at inflammatory sites.
IL-6 is the chief stimulator of the production of most acute
phase proteins [8], whereas the other implicated cytokines
influence subgroups of acute phase proteins. However, in
mice rendered incapable of expressing IL-6 (knockout mice),
the role played by IL-6 in stimulating the production of acute
phase proteins depends on the nature or site of the
inflammatory stimulus; the response is largely inhibited in IL-6
knockout mice injected with turpentine, but it is normal when
bacterial lipopolysaccharide is the inflammatory stimulus [9].
This finding indicates that lipopolysaccharide causes the
production of other cytokines that are capable of stimulating
the production of acute phase proteins [9].
Several cytokines, particularly IL-6, stimulate the production
of acute phase proteins in response to varied stimuli. The
patterns of cytokine production and of the acute phase
response differ in different inflammatory conditions. Acute
phase changes reflect the presence and intensity of
inflammation, and they have long been used as a clinical
guide to diagnosis and management.
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Using IL-6 gene knockout mice, Xing and coworkers [10]
identified an anti-inflammatory component to the action of IL-
6 in both local and systemic acute inflammatory responses
elicited by local lung or systemic exposure to endotoxin. They
demonstrated that IL-6 is critical in controlling the extent of
local and systemic acute inflammatory responses, particularly
the level of proinflammatory cytokines in the local and
systemic compartments.
Overall, in a normal host, one function of inducible IL-6 during
acute responses is to suppress the level of proinflammatory
cytokines without compromising the level of anti-inflammatory
cytokines [10,11]. In addition, IL-6 stimulates the production
of IL-1 receptor antagonist, which is an anti-inflammatory
mediator [12]. IL-6 therefore can have a protective effect.
The role of interleukin-6 in the development
of chronic inflammation
Given the actions of IL-6 to return the host to a homeostatic
state, it is clear that IL-6 operates to control the extent of
tissue inflammatory responses. In chronic diseases, typically
exemplified by immune stressors such as chronic intracellular
infections and tumours, IL-6 not only serves as an inducer of
acute phase reactions but also is an important player in eliciting
cellular immune responses to affected cells and mucosal
humoral responses directed against reinfection [13-18].
To be beneficial, the inflammatory reaction must be acute,
destroying an injurious agent within a short period of time and
in a localized area, while inducing an immune response. This
is achieved through a complex series of events characterized
by local leucocyte recruitment, death and migration [19]. The
transition from neutrophil to monocyte recruitment assists in
the efficient destruction of the inciting agent by the combined
destructive and phagocytic actions of neutrophils and
inflammatory macrophages. However, this transition also
assists the resolution of inflammation through eliminating
neutrophils and initiating an immune response.
IL-6 elicits not only acute phase reactions but also the
development of specific cellular and humoral immune
responses, including end-stage B cell differentiation,
immunoglobulin secretion and T cell activation. The main
switch from acute to chronic inflammation is the recruitment
of monocytes to the area of inflammation. IL-6 is important to
the transition between acute and chronic inflammation [11].
IL-6 plays a rather unexpected role in leucocyte recruitment in
vivo. A complex of IL-6 and sIL-6Rα can activate endothelial
cells to secrete IL-8 and monocyte chemoattractant protein
(MCP)-1, and induce expression of adhesion molecules [20].
Notably, IL-6 activation of endothelial cells occurs in vivo,
although these cells, like other stromal cells, express the
gp130 transducing protein of the IL-6 receptor complex but
not the 80 kDa ligand binding subunit, IL-6Rα; in vitro, such
activation could only be achieved when IL-6 was combined
with soluble recombinant IL-6Rα. Expression of IL-6Rα is
limited in humans to leucocyte and hepatocyte membranes
[20,21], but it can be shed from the neutrophil membrane as
a soluble form, which is found at high concentrations in
neutrophil enriched inflammatory fluids [22]. The sIL-6Rα
combines with IL-6 to bind gp130 on the membranes of
stromal cells, and activates these cells in a mechanism
termed trans-signalling (Figure 2).
The IL-6/IL-6Rα complex favours the transition from neutro-
phil to monocyte in inflammation [22,23]. The transition from
neutrophil to monocyte accumulation may be secondary to a
shift in the type of chemokine produced by stromal cells,
inflammatory macrophages or neutrophils [11]. Neutrophils
stimulated with inflammatory cytokines for several hours will
selectively produce MCP-1 and not IL-8 [24]. MCP-1
accumulation does not desensitize cells and leads to late
monocyte recruitment. Endothelial (or stromal cell) activation
by proinflammatory molecules leads to secretion of platelet
activating factor, IL-8 and IL-6, as well as leuco-endothelial
adhesion molecule expression. Chemoattractants, originating
from the endothelium or other cell sources, recruit neutrophils
and induce IL-6Rα shedding from their membranes. The
combination of IL-6Rα with IL-6 enables ligation to gp130 on
the endothelial cell membrane and increases both IL-6 and
MCP-1 endothelial (or stromal) cell secretion but not IL-8,
favouring a transition from neutrophil to monocyte recruitment
Figure 1
Kinetic of acute-phase protein production. Shown are the
characteristic patterns of change that occur in plasma concentrations
of some acute phase proteins after a moderate inflammatory stimulus.
Reprinted, with permission, from [5]. Copyright © 1987 Elsevier.Page 3 of 6
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[22,23] (Figure 2). IL-6 signalling through sIL-6Rα controls
leucocyte infiltration. In vitro studies confirm that sIL-6Rα
mediated events regulate both chemokine and adhesion
molecule expression. As a result, IL-6 trans-signalling controls
the intermediary factors that are involved in resolving
inflammation. A disruption in control of leucocyte trafficking,
for example by continuous IL-6 production, may therefore be
significant at the onset of chronic disease. IL-6 appears to
influence dramatically the nature of the immune response by
dictating the recruitment, activation and apoptotic clearance
of individual leucocyte subpopulations (e.g. neutrophils,
monocytes and lymphocytes) [25].
A transition from neutrophil to monocyte accumulation at the
site of inflammation suggests that there is a progression of
events that leads not only to monocyte recruitment but also to
disappearance of neutrophils. Neutrophils are central cells in
the defence of an organism against injury, notably infection,
through their capacity to synthesize oxygen metabolites and
to liberate various enzymes. However, these agents can also
be toxic to normal surrounding tissues and potentially induce
inflammatory diseases. As a result, there is rapid negative
regulation. Apoptotic neutrophils expressing new membrane
antigens are recognized by various receptors on
macrophages, leading to phagocytosis (Figure 2). This
phagocytosis of apoptotic polymorphonuclear neutrophils by
macrophages increases transforming growth factor-β and
MCP-1 secretion and decreases IL-8 production, leading to a
chemokine shift favouring monocyte recruitment. As neutro-
phils are depleted from the inflammatory site, blood mono-
cytes, in contrast, accumulate and differentiate into inflam-
matory macrophages, which complete phagocytosis and
destruction of the injurious agents [1-3]. The monocytes and
macrophages then emigrate after several days in the local
lymph nodes [26]. During this migratory process, monocytes
differentiate into dendritic cells, upregulating HLA class II
antigen membrane expression, and acquiring costimulatory
molecules such as CD80 and CD86 [27]. These cells may
then present antigenic peptides to lymphocytes, contributing
to the generation of an immune response.
IL-6 exhibits two contrasting features. In models of chronic
inflammatory diseases, such as collagen-induced arthritis,
murine colitis, or experimental autoimmune encephalomyelitis,
IL-6 is proinflammatory [28,29], whereas in models of acute
inflammation IL-6 exhibits an anti-inflammatory profile [10].
Available online http://arthritis-research.com/content/8/S2/S3
Figure 2
Possible role played by IL-6 in the shift from acute to chronic inflammation. Stage 1: following acute inflammatory response, IL-6 can bind with
sIL-6R. Stage 2: trans-signalling through gp130 leads to monocyte recruitment. Stage 3: prolonged IL-6 leads to neutrophilic apoptosis,
phagocytosis and mononuclear accumulation at the site of injury. IL, interleukin; JAK, Janus activated kinase; MCP, monocyte chemoattractant
protein; PMN, polymorphonuclear neutrophil; sIL-6R, soluble IL-6 receptor.Chronic inflammation, interleukin-6 and
disease
At the beginning of acute inflammation, IL-6 mediates the
acute phase responses. When its activity as a
proinflammatory cytokine persists, acute inflammation turns
into chronic inflammation that includes immune responses. In
chronic inflammation, IL-6 has a detrimental role that favours
mononuclear cell accumulation at the site of injury, through
continuous MCP-1 secretion, angioproliferation and anti-
apoptotic functions on T cells [30]. This may increase serum
levels of IL-6 and provide the basis for the amplification step
of chronic inflammatory proliferation. Plasmacytosis and
hyperplasia of synovial cells in the joints of patients with
rheumatoid arthritis (RA) are a typical example of chronic
inflammatory proliferation. In autoimmune diseases, IL-6 not
only maintains inflammation but also modifies the immune
responses.
Levels of circulating IL-6 are elevated in several inflammatory
diseases including RA (as mentioned above), systemic
juvenile idiopathic arthritis, systemic lupus erythematosus,
ankylosing spondylitis, psoriasis and Crohn’s disease. In RA
there is a correlation between IL-6 levels in synovial fluid and
markers of inflammation. In systemic juvenile idiopathic
arthritis there is a correlation between disease activity and
IL-6 levels. In lupus IL-6 levels are elevated, but in this setting
there is no relation to levels of C-reactive protein. IL-6 levels
in ankylosing spondylitis, psoriasis and Crohn’s disease are
also elevated and correlate with markers of disease activity.
Table 1 summarizes some of the research that has been
conducted in various disease models, using IL-6 deficient
mice and blockade of IL-6 signalling.
Conclusion
IL-6 has been shown to be a key player in chronic
inflammation, and IL-6 levels are elevated in inflammatory
diseases in humans. Expression of IL-6 is enhanced at the
site of inflammation, and blockade of IL-6 and IL-6 signalling
is effective at prevention and treatment in models of
inflammatory diseases (including arthritis and colitis).
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Table 1
IL-6 signalling blockade in different disease models
Finding Ref. Comment
Experimental arthritis
IL-6 is required for the development of collagen induced arthritis [31] IL-6–/– and IL-6+/+ mice
IL-6 plays a key role in the development of antigen induced arthritis [32] IL-6–/– mice
Blockade of IL-6 receptor ameliorates joint disease in murine collagen  [33]
induced arthritis
Soluble IL-6 receptor governs IL-6 activity in antigen-induced arthritis:  [34] IL-6–/– mice
blockade of arthritis severity by soluble gp130
Colitis
Blockade of IL-6 trans-signalling suppresses T cell resistance against  [30] Neutralization of sIL-6R by a gp130-Fc 
apoptosis in chronic intestinal inflammation fusion protein
IL-6 is required for the development of Th1 cell mediated murine colitis [35] C.B-17-scid mice transferred with 
CD45RBhigh CD4+ T anti-IL-6R mAb 
(MR16-1), used in a murine model of 
colitis
Modulating signalling
CIS3/SOCS3/SSI3 plays a negative role in STAT3 activation and  [36] Development of colitis as well as STAT3 
intestinal inflammation activation was significantly reduced in IL-6 
deficient mice
Induction of SOCS3/CIS3 as a therapeutic strategy for treating  [37] Recombinant adenovirus carrying the 
inflammatory arthritis CIS3 cDNA injected periarticularly into the 
ankle joints of mice with antigen induced 
arthritis or collagen induced arthritis
Models of infection




CIS, cytokine-induced SH2 protein; IL, interleukin; mAb, monoclonal antibody; sIL-6R, soluble IL-6 receptor; SOCS, suppressors of cytokine
signaling; SSI, STAT-induced STAT inhibitors; STAT, signal transducer and activator of transcription; Th, T-helper.Overall, IL-6 is important – indeed, critical under certain
conditions – to the development of persistent inflammation.
Therefore, it would be appropriate to continue to investigate
IL-6 blockade as an approach to treatment of chronic
inflammatory diseases.
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